Noa‑001
Inflammatory Bowel Disease
PreclinicalActive
Key Facts
About Noa Therapeutics
A biotech startup using biased AhR modulation to create disease‑modifying small‑molecule therapies for chronic inflammation.
View full company profileTherapeutic Areas
Other Inflammatory Bowel Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| Turq-101 | Turquoise Biotechnologies | Preclinical |
| GS-4875 | Gilead | Phase 2 |
| Function-based Consortium for IBD | PharmaBiome | Pre-clinical |
| Galapagos Collaboration | Scipher Medicine | Discovery/Pre-clinical |
| IBD Subclassification | Bio-Me | Research |
| Anti-iRhom2 antibodies | SciRhom | Pre-clinical |
| IBD Multi-omics Dataset | Ovation.io | Commercial |
| Inflectra | EMS | Phase 3 |
| IW-601 | ImmuneWalk Therapeutics | Preclinical |
| TRWR‑IBD | Taiwan Resonant Waves Research | Preclinical |
| Zymfentra™ | Celltrion | Marketed |
| IBD98-M | Holy Stone Healthcare | Preclinical |